Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 24

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 24
---
 on note payable(371,308)(392,002)Principal payments on financing lease(917,700)— Net cash provided by financing activities18,853,015 565,842 Effect of exchange rate changes on cash and cash equivalents and restricted cash 32,843 (1,729)Net change in cash, cash equivalents and restricted cash7,377,087 721,553 Cash and cash equivalents, beginning of period15,998,174 10,811,056 Cash and cash equivalents, end of period$23,375,261 $11,532,609 Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the consolidated balance sheets:Cash and cash equivalents23,075,261 11,232,609 Restricted cash included in other non-current assets300,000 300,000 Total cash, cash equivalents and restricted cash$23,375,261 $11,532,609 Supplemental disclosure of non-cash investing and financing activities:Operating right-of-use assets obtained in exchange for new operating lease liabilities, net$— $358,315 Additions to property and equipment and reduction of deposits$— $676,041 Financing right-of-use assets obtained in exchange for new financing lease liabilities$2,832,457 $— Prepaid rent reclassified to finance lease right-of-use asset$458,850 $— Additions to property and equipment included in accrued expenses and accounts payable$195,743 $— 

See accompanying notes.

5

Daré Bioscience, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (Unaudited)

1.    ORGANIZATION AND DESCRIPTION OF BUSINESS

Daré Bioscience, Inc. is a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real solutions. Daré Bioscience, Inc. and its wholly-owned subsidiaries operate in one segment. In this report, the “Company” refers collectively to Daré Bioscience, Inc. and its wholly-owned subsidiaries, unless otherwise stated or the context otherwise requires.The Company began assembling its diverse portfolio of assets in 2017 through acquisitions, exclusive in-licenses and other collaborations. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause, and aim to enhance outcomes